Table 1.

PARPi that have been trialed in patients with pancreatic cancer. Dosing and common toxicities information obtain from FDA prescribing information. For drugs that are not FDA approved, dosing information was obtained from the most recent clinical trial report.

PARPi	Properties⁶⁰	Dosing	Common Toxicities
Olaparib	Targets PARP1,2,3 and 4. Interacts with CYP	300 mg BID	Fatigue, anemia, thrombocytopenia, neutropenia
Rucaparib^{^}	Targets PARP1,2,3 and 4. Interacts with CYP	600 mg BID	Thrombocytopenia, anemia, nausea, fatigue
Veliparib^*	Weakest PARP trapping abillity	80 mg BID days 1–12 of 21 day cycles	Anemia, leukopenia, fatigue
Niraparib^{^}	High CNS penetration, off-target interactions with doapnmine, serotoning, norepinephrine receptors	200–300 mg daily	Nausea, thrombocytopenia, anemia, fatigue
Talazoparib^{^}	Most potent PARP-trapping ability, long half-life	1 mg daily	Anemia, neutropenia, thrombocytopenia
Fluzoparib^*	No CNS penetration. Trapping ability not yet defined	150 mg BID	Anemia, neutropenia

^*-

denotes agent is still investigational and not approved by the US FDA for any cancers.

^{^ -}

denotes drug is not approved by the US FDA for the treatment of pancreatic cancers, but has been approved for the treatment of other cancer types

BID: twice daily